Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2017 (Earliest event reported)
Reporting Period: Specific events occurring on August 8, 2017, and August 10, 2017.
Context: The filing discloses the entry into material definitive agreements involving debt financing and consulting services.
Key Financial Metrics and Obligations
This filing details the creation of new debt obligations rather than reporting operational financial performance (revenue, profit, or cash flow). The filing text does not provide a clear value for revenue, profit, cash flow, margins, or existing liquidity.
- Debt Instrument 1 (Eagle Equities - First Note): $200,000 principal; 8% interest; funded with cash; maturity August 8, 2018.
- Debt Instrument 2 (Eagle Equities - Back-End Note): $200,000 principal; 8% interest; initially offset by a Note Receivable; maturity August 8, 2018.
- Debt Instrument 3 (Regal Consulting - Consulting Note): $310,000 principal; 10% interest; fully earned upon signing; maturity August 10, 2019.
- Total New Principal Obligation: $710,000 (subject to cancellation conditions for the Back-End Note).
Material Changes and Agreements
The Company entered into two primary agreements creating direct financial obligations:
- Securities Purchase Agreement with Eagle Equities, LLC:
- Issuance of two 8% convertible redeemable junior subordinated promissory notes.
- Conversion Terms: Convertible into common stock at 60% of the lowest closing bid price for the ten trading days prior to conversion.
- Funding Structure: The First Note was cash-funded. The Back-End Note was initially paid via an offsetting Note Receivable due April 8, 2018. The Back-End Note requires cash funding prior to conversion and may be cancelled if specific trading price and volume conditions are not met.
- Default Provisions: Default triggers immediate payment and increases interest to 24% per annum.
- Consulting Agreement with Regal Consulting LLC:
- Retroactive to May 16, 2017, for services valued at a $310,000 convertible note.
- Conversion Terms: Convertible at the lesser of $1.50 or 65% of the three lowest trades in the ten trading days prior to conversion.
- Default Provisions: Default triggers immediate payment and increases interest to 18% per annum.
Guidance, Risks, and Unusual Items
Unusual Items and Risks:
- High Dilution Risk: Conversion prices are set at significant discounts (60% and 65%) to recent trading prices, which could result in substantial dilution to existing shareholders upon conversion.
- Default Interest Penalties: Both financing arrangements include punitive default interest rates (24% and 18%) significantly higher than standard rates.
- Conditional Funding: The $200,000 Back-End Note is contingent on maintaining minimum trading prices and volume; failure to meet these conditions results in immediate cancellation of the note and the associated Note Receivable.
- Unregistered Sales: Securities were issued under Section 4(a)(2) of the Securities Act of 1933, exempt from registration as private transactions.
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial projections.
Investor Verification Checklist
- Verify the current trading volume and price of Propanc Biopharma common stock to assess the likelihood of the Back-End Note funding conditions being met.
- Calculate the potential dilution impact if all $710,000 in notes are converted at the specified discount rates (60% and 65% of recent lows).
- Review the Company's cash position to determine its ability to service the 8% and 10% interest accruals or repay principal at maturity.
- Confirm the status of the Note Receivable due April 8, 2018, and whether the offsetting Back-End Note remains active.
- Examine the specific "events of default" defined in the attached exhibits to understand triggers for the 24% and 18% penalty interest rates.